Chief Executive Officer of Novartis Saudi Arabia since June 2025.

Amir Abdelaziz is an executive leader specializing in the pharmaceutical industry, with expertise spanning Saudi healthcare transformation, pharmaceutical innovation, and investment in the life sciences sector.

He has over 20 years of experience in the pharmaceutical sector across the Middle East, Africa and Asia-Pacific region, where he held a number of regional leadership positions at Novartis, including: 

• Region Therapy Area Head for Immunology across Asia Pacific, Middle East, and Africa based in Singapore
• Head of Immunology unit Gulf Cluster & Gulf LT member
• Senior Leadership Team Member (Gulf)
• Head of Ophthalmology & Gene therapy unit Gulf cluster.

Amir focuses on building strategic partnerships that advance clinical research and innovation, while developing national competencies and leadership capabilities. as well as exploring ways to deliver advanced, innovative treatments through the latest technologies, including artificial intelligence, within the Kingdom.

Under his leadership, Novartis Saudi Arabia was recognized by the Saudi Food and Drug Authority (SFDA) as the largest multinational contributor to clinical trials in the Kingdom in 2025.

He obtained a Bachelor of Science in Pharmacy from Cairo University in 2004.